Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urination disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Urination disorders. Displaying page 1 of 1.
    EudraCT Number: 2012-000957-30 Sponsor Protocol Number: 191622-117 Start Date*: 2012-08-28
    Sponsor Name:Allergan Ltd.
    Full Title: BOTOX® for the Treatment of Urinary Incontinence due to Neurogenic Detrusor Overactivity in Patients with Multiple Sclerosis
    Medical condition: Urinary incontinence due to neurogenic detrusor overactivity (NDO) resulting from multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001268-57 Sponsor Protocol Number: 905-CL-058 Start Date*: 2007-09-12
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate with 0.4 mg Tamsulosin Hydrochlo...
    Medical condition: Storage and Voiding Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027561 Micturition disorder LLT
    9.1 10005053 Bladder neck obstruction LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004898-30 Sponsor Protocol Number: 191622-121 Start Date*: 2013-07-18
    Sponsor Name:Allergan Ltd
    Full Title: Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age
    Medical condition: Urinary Incontinence due to Neurogenic Detrusor Overactivity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) AT (Completed) IT (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004036-36 Sponsor Protocol Number: 178-MA-1008 Start Date*: 2016-07-18
    Sponsor Name:Astellas Pharma Global development, Inc
    Full Title: A Phase 4, Double-Blind, Randomized, Placebo-controlled, Multi- Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While ...
    Medical condition: Over active bladder (OAB) in men with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000507-44 Sponsor Protocol Number: D-FR-52120-223 Start Date*: 2016-06-29
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...
    Medical condition: Urinary incontinence caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) FR (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000464-17 Sponsor Protocol Number: 191622-137 Start Date*: 2014-06-17
    Sponsor Name:Allergan Limited
    Full Title: BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age
    Medical condition: Urinary Incontinence Due to Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) NO (Completed) PL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004877-26 Sponsor Protocol Number: 191622-120 Start Date*: 2013-07-18
    Sponsor Name:Allergan Ltd.
    Full Title: BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age
    Medical condition: Urinary Incontinence Due to Neurogenic Detrusor Overactivity
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) AT (Completed) IT (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004540-22 Sponsor Protocol Number: AGO/2011/009 Start Date*: 2011-10-25
    Sponsor Name:Ghent University Hospital
    Full Title: Desmopressin melt therapy in nocturnal polyuria patients: pharmacokinetic/dynamic study
    Medical condition: Nocturia and noctural polyuria
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10064016 Nocturnal polyuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004560-29 Sponsor Protocol Number: AGO/2011/010 Start Date*: 2011-10-25
    Sponsor Name:Ghent University Hospital
    Full Title: Desmopressin melt therapy in nocturnal polyuria patients: pharmacodynamic study
    Medical condition: Noctural polyuria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10064016 Nocturnal polyuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003471-30 Sponsor Protocol Number: D-FR-52120-222 Start Date*: 2016-09-26
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONE OR MORE INTRADETRUSOR TREATMENTS OF 600 OR 800 UNITS OF DYSPORT...
    Medical condition: Urinary incontinence (UI) caused by neurogenic detrusor overactivity due to either spinal cord injury or multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed) PT (Completed) CZ (Completed) IT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003701-25 Sponsor Protocol Number: 7035-CL-0014 Start Date*: 2013-12-09
    Sponsor Name:Tacurion Pharma Inc
    Full Title: A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio ...
    Medical condition: Nocturia associated with nocturnal polyuria
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064016 Nocturnal polyuria LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021556-25 Sponsor Protocol Number: IBSA 01-2010 Start Date*: 2011-02-24
    Sponsor Name:IBSA
    Full Title: Phase III, randomized, open-label, multicenter evaluation of efficacy and tolerability `of Ialuril (sodium hyaluronate-chondroitin sulfate) vs. dimethyl sulfoxide (DMSO) in women with interstitial ...
    Medical condition: Interstitial Cystitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018188 HLGT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020172-30 Sponsor Protocol Number: 191622-100 Start Date*: 2010-08-16
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Intraprostatic Administration of BOTOX® 200 U (Botulinum Toxin Type A) Purified Neur...
    Medical condition: Treatment of Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) BE (Completed) FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002067-18 Sponsor Protocol Number: B12CS-B13CS Start Date*: 2018-12-11
    Sponsor Name:Advicenne
    Full Title: A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses...
    Medical condition: Cystinuria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011778 Cystinuria PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-018118-21 Sponsor Protocol Number: OXN2503 Start Date*: Information not available in EudraCT
    Sponsor Name:Mundipharma Research GmbH & Co. KG
    Full Title: An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to place...
    Medical condition: Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10008927 Chronic interstitial cystitis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005455-37 Sponsor Protocol Number: 178-CL-207 Start Date*: 2022-11-14
    Sponsor Name:Astellas Pharma Global Development Inc.
    Full Title: A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron P...
    Medical condition: Neurogenic detrusor overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10012547 Detrusor hyperreflexia LLT
    23.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005307-33 Sponsor Protocol Number: P00048GP403 Start Date*: 2012-09-24
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH, A multinational, multi...
    Medical condition: The aim of the proposed study is to assess the activity on inflammation biomarkers of L.S.E.S.r (PERMIXON® 160mg hard capsule) and Tamsulosine LP in the treatment of BPH. The potential links betwee...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10004447 Benign prostatic hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) ES (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002988-25 Sponsor Protocol Number: B21CS Start Date*: 2015-10-22
    Sponsor Name:Advicenne Pharma
    Full Title: A multicentre, open-label, non-inferiority sequential study, evaluating the efficacy, safety, tolerability and acceptability of ADV7103 compared to standard of care in distal renal tubular acidosis...
    Medical condition: distal renal tubular acidosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038359 - Renal and urinary disorders 10038535 Renal tubular acidosis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022111-19 Sponsor Protocol Number: FDC114615 Start Date*: 2010-11-22
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: Study FDC114615: Comparative efficacy of DuodartTM plus lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naïve men wi...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (Completed) FR (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 06:07:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA